A new research has revealed that a team of researchers hunting for new Ebola treatments have come up with "groundbreaking" artificial-intelligence that can predict the effectiveness of new medicines 150 times faster than current methods.
A startup supported by the University of Toronto, Chematria, programmed Canada's fastest supercomputer with an algorithm that simulates and analyzes "millions of potential medicines" to predict their effectiveness against Ebola, Mashable reported.
The cofounder and CEO of Chematria, Abraham Heifets, said that what they are attempting would have been considered science fiction, until now as they are going to explore the possible effectiveness of millions of drugs, something that used to take decades of physical research and tens of millions of dollars, in mere days with their technology.
Chematria claims that the technology is a virtual drug-discovery platform that helps pharmaceutical companies to determine which molecules can become medicines.
.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
